A Study of MGC028 in Participants With Advanced Solid Tumors
NCT06723236
This study is recruiting at 7 US sites in 6 states, according to its ClinicalTrials.gov record last updated .
Summary
The goal of this clinical trial is to characterize the safety, tolerability, dose-limiting toxicities (DLT), and maximum tolerated dose (MTD) or maximum administered dose of MGC028 (if no MTD is defined). The study will enroll adult participants with relapsed or refractory, unresectable, locally advanced of metastatic solid tumors known to express ADAM9. The main question the study aims to answer is: What types of side effects will participants experience when receiving MGC028?
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Advanced Solid Tumors
- NSCLC Adenocarcinoma
- Cholangiocarcinoma
- Pancreatic Carcinoma
- Colorectal Carcinoma
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- MacroGenics
- Last updated on ClinicalTrials.gov
- April 27, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- UCSF - Helen Diller Family Cancer Center · San Francisco, CA
Massachusetts · 2
- Dana Farber/Harvard Cancer Center · Boston, MA
- Mass General Brigham · Boston, MA
Michigan · 1
- South Texas Accelerated Research Therapeutics (START) Midwest · Grand Rapids, MI
New York · 1
- Icahn School of Medicine at Mt. Sinai · New York, NY
Texas · 1
- South Texas Accelerated Research Therapeutics (START) San Antonio · San Antonio, TX
Utah · 1
- South Texas Accelerated Research Therapeutics (START) Mountain Region · West Valley City, UT
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.